Browsing by Subject "Riskinjakomalli"

Sort by: Order: Results:

Now showing items 1-1 of 1
  • Roslin, Waltter Frank Oliver (Helsingin yliopisto, 2020)
    From 2017 pharmaceutical companies have had the option to apply for conditional reimbursement. With a temporary legislative experiment, the government intended for a more facilitated introduction of novel medicines as well as to enable access to new products for the patients who needed them. Additionally, conditional reimbursement was used to ensure Juha Sipiläs governments cuts on the pharmaceutical expenditures and explore the compatibility of the new risk-sharing measure with the Finnish reimbursement scheme. In recent years, Risk-sharing in pharmaceutical reimbursements has increased in Europe to mitigate uncertainties relating to new medicines. At the core of the risk-sharing model is the confidential risk-sharing agreement negotiated between the company and the government. In its current practice, all these agreements have been financial based. The application of conditional reimbursement has increased the number of available products and most likely positively impacted the patients access to treatment. The research was conducted mainly as a doctrinal analysis, while also utilising law and economics when comparing the current Health Insurance Act (1224/2004) regarding conditional reimbursement, and the related preparatory works of the government to other legislation and the result of the experiment. Based on the analysis an interpretation was given regarding the compatibility of conditional reimbursement for the Finnish reimbursement scheme, as well as proposals for its alterations. The research showed that conditional reimbursement has a good possibility to become a permanent part of the Finnish reimbursement scheme, however changes to the current practice needs to be made. The confidentiality of the agreements has reduced the transparency of the reimbursement scheme. Transparency should be added with accepting a new agreement type and through increasing the number of performance-based agreements. Additionally, there is a new for more research concerning the economic impact of the experiment over reimbursement expenditures and the increases of the levels of social welfare. However, based on the gathered data the compatibility of conditional reimbursement for the Finnish reimbursement scheme can be vouched for.